Innate Pharma Ownership | Who Owns Innate Pharma?


OverviewForecastRevenueFinancialsChartTranscripts

Innate Pharma Ownership Summary


Innate Pharma is owned by 0.30% institutional investors, and 99.70% retail investors. Optiver b.v. is the largest institutional shareholder, holding 0.11% of IPHA shares. Range Cancer Therapeutics ETF is the top mutual fund, with 0.10% of its assets in Innate Pharma shares.

IPHA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockInnate Pharma0.30%-99.70%
SectorHealthcare Stocks 47.31%8.01%44.69%
IndustryBiotech Stocks 45.43%7.81%46.75%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Optiver b.v.87.35K0.11%$169.46K
Exchange traded concepts86.24K0.11%$167.30K
Morgan stanley43.52K0.05%$84.44K
Citadel advisors23.53K0.03%$45.64K
Barclays412.000.00%$1.00K
Ubs group297.000.00%$576.00
Rhumbline advisers205.000.00%$397.00
Steward partners investment advisory200.000.00%$388.00
Millennium management---
Jane street group---

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Exchange traded concepts86.24K0.00%$167.30K
Optiver b.v.87.35K0.00%$169.46K
Jane street group---
Rhumbline advisers205.00-$397.00
Barclays412.00-$1.00K
Ubs group297.00-$576.00
Citadel advisors23.53K-$45.64K
Morgan stanley43.52K-$84.44K
Millennium management---
Steward partners investment advisory200.00-$388.00

Top Buyers

HolderShares% AssetsChange
Citadel advisors23.53K-23.53K
Optiver b.v.87.35K0.00%16.79K
Ubs group297.00-87.00
Steward partners investment advisory200.00--
Rhumbline advisers205.00--

Top Sellers

HolderShares% AssetsChange
Exchange traded concepts86.24K0.00%-26.83K
Jane street group---14.55K
Millennium management---10.58K
Morgan stanley43.52K--600.00
Rhumbline advisers205.00--

New Positions

HolderShares% AssetsChangeValue
Citadel advisors23.53K-23.53K$45.64K

Sold Out

HolderChange
Millennium management-10.58K
Jane street group-14.55K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20248-11.11%241,754-4.79%-301.68%3-25.00%2-
Mar 31, 2024912.50%253,91896.97%-1240.88%4100.00%2-33.33%
Dec 31, 20238-128,912-59.51%-102.15%2100.00%3-
Sep 30, 20238-11.11%318,40735.34%-460.53%1-66.67%3-25.00%
Jun 30, 2023912.50%235,270-40.73%-137.18%350.00%433.33%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Range Cancer Therapeutics ETF77.35K0.10%-
ActivePassive International Equity ETF66.08K0.08%-

Recent Insider Transactions


DateNameRoleActivityValue

Insider Transactions Trends


DateBuySell

IPHA Ownership FAQ


Who Owns Innate Pharma?

Innate Pharma shareholders are primarily institutional investors at 0.30%, followed by 0% insiders and 0% retail investors. The average institutional ownership in Innate Pharma's industry, Biotech Stocks , is 45.43%, which Innate Pharma falls below.

Who owns the most shares of Innate Pharma?

Innate Pharma’s largest shareholders are Optiver b.v. (87.35K shares, 0.11%), Exchange traded concepts (86.24K shares, 0.11%), and Morgan stanley (43.52K shares, 0.05%). Together, they hold 0.27% of Innate Pharma’s total shares outstanding.

Does Blackrock own Innate Pharma?

BlackRock is not among the top 10 institutional shareholders of Innate Pharma.

Who is Innate Pharma’s biggest shareholder by percentage of total assets invested?

Exchange traded concepts is Innate Pharma’s biggest shareholder by percentage of total assets invested, with 0.00% of its assets in 86.24K Innate Pharma shares, valued at 167.3K$.

Who is the top mutual fund holder of Innate Pharma shares?

Range Cancer Therapeutics ETF is the top mutual fund holder of Innate Pharma shares, with 0.10% of its total shares outstanding invested in 77.35K Innate Pharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools